Print

MCA-0835

A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers

Trial Details:

I Completed
Rockefeller University January 01, 2014
3BNC117 3BNC117 antibody
3BNC117 Passive Immunization
Germany, USA 49
NCT02018510
https://clinicaltrials.gov/show/NCT02018510